Skip to content

Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP‐1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial

Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11463 - 11474 · 0 citations · 23 references
Medicine

Abstract

To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of the dual GLP‐1R/GIPR agonist BGM0504 in Chinese adults with overweight or obesity without diabetes.

View source

Similar papers

Review Open access Sep 2026

Efficacy and Safety of Dual GLP‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

Dual glucagon‐like peptide‐1/glucagon receptor (GLP‐1/GCGR) agonists represent a novel obesity treatment class, but existing meta‐analyses often conflate them with GIP‐containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class‐specific efficacy and safety incompletely character...

M. Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · 0 citations
Open access Sep 2026

Preclinical and First‐In‐Human Evaluation of Ribupatide (HRS9531), a Dual GLP‐1/GIP Receptor Agonist

This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors.

K. He, Yi-Lin Wei, Heng-Li Zhao et al. · 0 citations
Open access Oct 2026

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.

Jun-Sung Moon, K. Han, Dong-Lim Kim et al. · 0 citations
Open access Sep 2026

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

This study assessed the real‐world effectiveness and safety of a fixed‐dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM).

Wei-Jian Ke, Ying-Hong Kong, Song-Bo Fu et al. · 0 citations
Review Open access Sep 2026

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of disconti...

Vikash Singhani, M. Ehsan, Sara Valencia et al. · 0 citations
Open access Sep 2026

Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population r...

Hussain Salim, Shaheer Qureshi, G. Gulsin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.